ImaginAb signs collaboration deal with 3 firms

By staff writers

October 15, 2019 -- Imaging agent developer ImaginAb has signed a collaboration agreement with pharmaceutical companies AstraZeneca, Pfizer, and Takeda Pharmaceutical to further the clinical development of its CD8 PET technology.

The three firms will help guide a current clinical trial that's evaluating the utility and value of CD8 ImmunoPET in immuno-oncology drug development, according to ImaginAb. In exchange, they will receive early access to clinical and imaging data and be able to contribute to the post-trial data analysis, ImaginAb said.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking